Ola Landgren, MD, PhD, from Memorial Sloan Kettering Cancer Center, NY, describes novel uses for minimal residual disease (MRD) measurement in multiple myeloma (MM), including his experience of monitoring MRD ‘over time’, how we might think of the definition of relapse going forward, and the studies his institute is working on in these areas. This video was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
New applications for MRD measurement: MRD ‘over time’
